ArticlePDF Available

Separation and Determination of Process-Related Impurities of Erlotinib Using Reverse-Phase HPLC with a Photo-Diode Array Detector

Authors:

Abstract and Figures

A simple and rapid reverse-phase high-performance liquid chromatographic (HPLC) method for the simultaneous separation and determination of erlotinib and its process-related impurities in bulk drugs has been developed. Five process-related impurities of erlotinib have been separated on an Inerstsil ODS-3V (C18) column and detected at 254 nm using a photo diode array (PDA). This HPLC method was successfully applied to the analysis of erlotinib bulk drug. The recoveries of erlotinib and process-related impurities were in the range of 92.86-106.23%, and found to be specific, precise and reliable for the determination of unreacted raw materials, intermediates in the reaction mixtures and bulk drugs.
Content may be subject to copyright.
ANALYTICAL SCIENCES MARCH 2012, VOL. 28 305
Erlotinib hydrochloride, 6,7-bis(2-methoxyethoxy)-N-(3-
ethynylphenyl)quinazolin-4-amine (Tarceva, R 1415, CP 358774,
OSI 774, NSC 718781), is a drug used to treat non-small cell
lung cancer, pancreatic cancer and several other types of cancer.
It is a tyrosine kinase inhibitor, which acts on the epidermal
growth factor receptor (EGFR). Erlotinib hydrochloride is an
orally active small molecule epidermal growth factor receptor
(HER1/EGFR) inhibitor approved in the United States and
Switzerland for the treatment of refractory locally advanced or
metastatic non-small cell lung cancer.1 Erlotinib was synthesized
from 6,7-bis-(2-methoxyethoxy)quinazolin-4-(3H)-one, which
in turn was prepared in an efficient way from commercially
available 3,4-dihydroxy benzaldehyde. Further, the compound
was reacted with thionyl chloride at reflux temperature to obtain
4-chloro-6,7-bis-(2-methoxyethoxy)quinazoline; this, upon
treatment with 3-ethynylaniline in DMF yielded erlotinib·HCl.2
The raw material and intermediates formed during the synthesis
may be present in bulk drug as an impurity; according to the
USFDA such impurities present at the levels of greater than
0.1% must be identified and quantified using validated analytical
procedures. The quality of erlotinib not only depends on the
adopted procedure, but also on the synthetic precursors,
side-reaction products, unreacted raw materials and
intermediates, since they may possess unwanted toxicological
effects. Hence, thorough monitoring of related substances is of
higher importance for controlling the quality of erlotinib in the
final product. HPLC is the technique of choice for the separation
and estimation of related impurities in pharmaceutical
formulations. A thorough literature survey has indicated several
HPLC methods for the determination of erlotinib·HCl in
pharmaceutical formulations as well as in biological fluids using
ultra-violet and mass spectra detection.3
8 The HPLC method
was developed for the assay of erlotinib in the presence of
degradation products.9 The analysis of erlotinib and its
metabolites is conducted in rat tissue sections by MALDI
quadrupole time-of-flight mass.10 A specific method for
determination of erlotinib (OSI-774) and its metabolite
desmethyl erlotinib (OSI-420) in human plasma involves using
liquid chromatography
tandem mass spectrometry.7 All of these
methods were used for estimating erlotinib in pharmaceutical
formulations, bulk drugs and their metabolites in biological
fluids. A literature survey revealed that there is no HPLC
method for a simultaneous estimation of erlotinib and its
process-related impurities. The present work describes a simple
and rapid isocratic HPLC method for the simultaneous
determination of erlotinib and its process-related impurities.
This method is suitable for the quality assessment of erlotinib in
bulk drugs in the presence of process impurities. The developed
method was validated with respect to accuracy, precision,
linearity and ruggedness.
Experimental
Reagents and chemicals
All reagents were of analytical grade unless stated otherwise.
HPLC-grade water was provided by a Milli-Q® water purification
system, Millipore Corp. (USA), HPLC-grade acetonitrile and
ammonium acetate procured from Merck India Ltd. (India).
Apparatus
The HPLC system included two LC-10AT VP pumps, an
SPD-M10A VP photo-diode array detector, a CTO-10AS VP
oven and SCL-10A VP controller (all from Shimadzu, Japan).
A reverse-phase Inertsil ODS-3V (GL Sciences Inc., Japan)
column (25 cm × 4.6 mm i.d.; particle size, 5 μm) was used for
separation, and chromatograms were integrated using Class vp
software.
Chromatographic conditions
The mobile phase was 1% ammonium acetate and acetonitrile
(55:45 v/v); before delivering into the column it was filtered
through a 0.45-μm nylon filter and degassed. The analysis was
carried out under isocratic condition using a flow rate of
2012 © The Japan Society for Analytical Chemistry
To whom correspondence should be addressed.
E-mail: gcreddy@vmsrf.org
Separation and Determination of Process-Related Impurities of Erlotinib
Using Reverse-Phase HPLC with a Photo-Diode Array Detector
Chandrashekara KARUNAKARA, Udupi APARNA, Venkateshappa CHANDREGOWDA, and
Chandrasekara G. REDDY
Vittal Mallya Scientific Research Foundation (VMSRF), #94/3 & 94/5, 23 Cross, 29 Main, BTM II Stage,
Bengaluru-560076, India
A simple and rapid reverse-phase high-performance liquid chromatographic (HPLC) method for the simultaneous
separation and determination of erlotinib and its process-related impurities in bulk drugs has been developed. Five
process-related impurities of erlotinib have been separated on an Inerstsil ODS-3V (C18) column and detected at 254 nm
using a photo diode array (PDA). This HPLC method was successfully applied to the analysis of erlotinib bulk drug. The
recoveries of erlotinib and process-related impurities were in the range of 92.86
106.23%, and found to be specific,
precise and reliable for the determination of unreacted raw materials, intermediates in the reaction mixtures and bulk drugs.
(Received June 22, 2011; Accepted December 3, 2011; Published March 10, 2012)
Notes
306 ANALYTICAL SCIENCES MARCH 2012, VOL. 28
1.0 ml/min at 30°C. Chromatograms were recorded at 254 nm
using a PDA detector.
Analytical procedure
Solutions of (1000 μg/ml) erlotinib and its process-related
impurities were prepared by dissolving known amounts of
components in a mobile phase. These solutions were further
diluted to determine the accuracy, precision, linearity and limit
of detection and limit of quantification.
Results and Discussion
Optimization of chromatographic conditions
Figure 1 shows the synthetic process for the synthesis of
erlotinib. It can be seen from Fig. 1 that there are five
compounds that include the starting material and intermediates
that could be present as a potential impurity in erlotinib. The
present study was aimed at developing a chromatographic
system capable of eluting and separating erlotinib and its
synthetic impurities.
All of the impurities and erlotinib were subjected to separation
by reverse-phase HPLC using different columns and mobile
phases. The separation and peak shapes were good on Inertsil
ODS-3V (4.6 × 250 mm, 5 μm) column using 1% ammonium
acetate and acetonitrile (55:45 v/v). A typical chromatogram of
erlotinib spiked with 25 ppm of each impurity is shown in
Fig. 2. It is evident from Fig. 2 that all of the compounds were
eluted and well separated with good peak shapes and resolutions.
The UV wavelength at 254 nm was chosen for detection and
quantification, since erlotinib and its impurities have good
absorption at that wavelength. The peaks were identified by
injecting and comparing the retention times of individual
compounds and studying the absorption spectra using a PDA
detector (Fig. 3). The developed method was validated with
respect to accuracy, precision, linearity and robustness.
Specificity
To demonstrate the specificity of the method, erlotinib bulk
drug was spiked with known amounts of impurities, and
chromatographed. All of the impurities were well separated
from erlotinib; the chromatographic peak purity and the
homogeneity were evaluated with a PDA detector. The peaks
with a flat-top indicated that erlotinib has a homogeneous peak
with no impurities embedded in it. Also, the specificity was
checked by stressing pure erlotinib under UV light at 254 nm,
and under extreme conditions, such as 0.1 N NaOH, 0.3 N HCl
and 3% H2O2 at 60°C for 24 h. Under UV and acidic conditions
there was no change in the purity, but in alkaline and oxidative
conditions the degradation products were formed. However,
they are well separated from erlotinib and the process impurities,
indicating that the method is specific for the separation and
estimation of erlotinib and its process impurities. It can be seen
from the HPLC chromatogram of erlotinib bulk drug (Fig. 4)
that the process-related impurities were well separated from
unknown impurities.
System suitability
The system suitability was evaluated by using 0.1% of all
impurities spiked to erlotinib (100 μg/ml), and evaluated by
making five replicate injections. The system suitability
parameters (retention time (tR), relative retention time (RRT)
and tailing factors) were evaluated, and are recorded in Table 1.
Linearity
The linearity of the detector response to different concentrations
of impurities was studied by analyzing erlotinib spiked with
each impurity at seven levels ranging over 0.1
2.0 μg/ml;
similarly, the linearity of erlotinib was studied by preparing
standard solutions at seven different levels, ranging over
25
300 μg/ml. The data were subjected to statistical analysis
using linear-regression model. The correlation coefficients (R2)
for erlotinib and its impurities were in the range of 0.995
0.999.
OH
OH
CHO O
O
CHO
H
3
CO
H
3
CO
O
O
CN
H
3
CO
H
3
CO
70% HNO
3
50 °C
O
O
CN
H
3
CO
H
3
CO NO
2
O
O
H
3
CO
H
3
CO
NH
N
O
O
O
H
3
CO
H
3
CO
N
N
NH
CH
pyridine, NH
2
OH.HCl
1-bromo-2-methoxyethane,
3 - ethynylaniline, DMF
SOCl
2
, reflux
80°C
80% N
2
H
4
.H
2
O
FeCl
3
, aq.CH
3
OH
HCl/HCOOH
90 - 130 °C
.HCl
E
0
E
1
E
2
E
3
E
4
E (Erlotinib HCl)
K
2
CO
3
, DMF
100 °C
Fig. 1Process for the synthesis of erlotinib.
Fig. 2Typical chromatogram of erlotinib (E) spiked with 25 ppm of
each impurity (E0, E1, E2, E3 and E4).
ANALYTICAL SCIENCES MARCH 2012, VOL. 28 307
Accuracy and precision
The accuracy of the method for impurities was checked by
spiking each impurity at three different concentration levels,
ranging over 0.1
1.0 μg/ml (0.1, 0.4 and 1.0 μg/ml) to the
erlotinib at a specified level (100 μg/ml). All estimations were
made in triplicate (n = 3); the recoveries for all five impurities
were found to be 92.86
106.23%. The precision of the method
for impurities was tested by injecting six individual preparations
of 100 μg/ml of erlotinib spiked with 0.1 μg/ml of each
impurity. The recoveries of each impurity were calculated, and
the RSD was found to be in the range of 1.07
3.27%.
The accuracy and precision for determining the assay of
erlotinib was checked at three different levels: i.e., 50, 100 and
200 μg/ml each, in triplicate. Also, the RSD values were found
to be below 1.0%. The intermediate precision is the inter-day
variation at the same concentration levels determined on
Fig. 3Comparative UV absorption spectra of impurities (E0, E1, E2, E3 and E4) in standard and bulk drugs.
Fig. 4Typical chromatogram of a bulk drug (Uk, unknown
impurity).
308 ANALYTICAL SCIENCES MARCH 2012, VOL. 28
successive days. The inter-day variations calculated for three
concentration levels are expressed in terms of RSD, %. At each
concentration level, the RSD, % values were below 1.5%,
indicating a good intermediate precision.
Robustness
In order to evaluate the robustness of the method, the influence
of a small and deliberate variation of the analytical parameters
on erlotinib and its impurities was studied. The robustness was
studied by varying ±0.2 ml of the flow rate, ±2 ml of the
acetonitrile composition in the mobile phase and ±2°C in the
column temperature to the actual method parameters. In all of
the above variations, test samples were injected in triplicate.
There was a slight change in the retention times of erlotinib and
its impurities upon changing the mobile-phase concentration,
but all peaks were well separated without affecting the accuracy
of the quantitative estimation of erlotinib and the impurities.
There was no significant change observed upon changing the
flow rate and the temperature. The result indicates that the
method is suitable for the separation and estimation of erlotinib
and its synthetic impurities.
Limit of detection and quantification
The limit of detection (LOD) and quantification (LOQ)
represent the concentrations of the analytes that would yield a
signal-to-noise ratio of 3 for LOD and 10 for LOQ, respectively.
LOD and LOQ were determined by measuring the magnitude of
the analytical background by injecting blank samples and
calculating the signal-to-noise ratio for each compound by
injecting a series of solutions until the S/N ratio is 3 for LOD
and 10 for LOQ. LOD and LOQ of all compounds lie in the
range of 0.016
0.029 and 0.045
0.095 μg/ml, respectively.
Analysis of samples
First, accurately weigh 200 mg of an erlotinib bulk drug
sample into a 100-ml volumetric flask, and dissolve in the
mobile phase and make up. This solution was used to estimate
impurities. The impurities in bulk drug samples were identified
by comparing the retention times and the UV spectral curves
with that of standard impurities. The results are recorded in
Table 2. Almost all impurities were found in different quantities
in all studied samples. Erl-2 has the highest amount of impurity
(0.14%), of which impurity E4 alone was 0.05%. The assay for
determining erlotinib when carried out by diluting the above
solution to 200 ppm with the mobile phase ranged from 99.67 to
99.80%.
Conclusions
A simple reverse phase-HPLC method was developed and
validated for the simultaneous estimation of erlotinib and its
process-related impurities in erlotinib bulk drug. This method is
selective, sensitive and precise for estimating erlotinib and its
process-related impurities, which may be present in trace levels
in bulk drugs.
Acknowledgements
We thank Dr. Anil Kush, CEO, Vittal Mallya Scientific Research
Foundation, for his encouragement and support.
Supporting Information
Tables containing linearity data, recovery data, precision data,
intra-day and inter-day precision assay, robustness data and
assay results of bulk drug erlotinib and its impurities (Tables S1
S6) are reported in supporting information. This material is
available free of charge on the Web at http://www.jsac.or.jp/
analsci/.
References
1. J. Dowell, J. D. Minna, and P. Kirkpatrick, Nat. Rev. Drug
Discovery, 2005, 4, 13.
2. V. Chandregowda, G. Venkateswara Rao, and G.
Chandrasekara Reddy, Heterocycles, 2007, 71, 39.
3. J. Pan, X. Jiang, and Y. L. Chen, Pharmaceutics, 2010, 2, 105.
4. F. Chiadmi, M. Duprez, J. Schlatter, and J. E. Fontan, EJHP
Science, 2007, 13, 48.
5. E. R. Lepper, S. M. Swain, A. R. Tan, W. D. Figg, and A.
Sparreboom, J. Chromatogr., B, 2003, 796, 181.
6. R. Honeywell, K. Yarzadah, E. Giovannetti, N. Losekoot,
E. F. Smit, M. Walraven, J. S. W. Lind, C. Tibaldi, H. M.
Verheul, and G. J. Peters, J. Chromatogr., B, 2010, 878, 1059.
7. M. Zhao, P. He, M. A. Rudek, M. Hidalgo, and S. D. Baker,
J. Chromatogr., B, 2003, 793, 413.
8. M. C. Prieto Conaway, H. Bui, S. Beachy, R. Pitoniak, B.
Hylander, P. Wang, K. Marlar, E. Repasky, and L. Kazim, J.
Chromatogr., B, 2010, 878, 1059.
9. S. S. Pujeri, A. M. A. Khader, and J. Seetharamappa, Anal.
Lett., 2009, 42, 1855.
10. L. Signor, E. Varesio, R. F. Staack, V. Starke, W. F. Richter,
and G. Hopfgartner, J. Mass Spectrom., 2007, 42, 900.
Table 1System suitability data
Compound Abbrevia tion tR/min RRT Tailing factor λmax/nm (ε)
3,4-Dihydroxy benzaldehyde
3,4-Dimethoxy benzaldehyde
3,4-Dimethoxy benzonitrile
4,5-Dimethoxy-2-nitrobenzonitrile
6,7-Bis-(2-methoxyethoxy)quinazolin-4-(3H)-one
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-
quinazolinamine (erlotinib)
E0
E1
E2
E3
E4
E
4.473
6.75
8.948
11.904
2.997
15.091
0.30
0.45
0.59
0.79
0.20
1
1.16
1.26
1.20
1.08
1.13
1.03
284 (18536)
231 (20889)
254 (15341)
252 (26380)
241 (57506)
246 (42966)
Table 2Results of analysis of bulk drugsa
Sample
Impurities, % (w/w) ± %RSD
E0E1E2E3E4
Erl-1
Erl-2
Erl-3
0.01 ± 1.29
0.02 ± 0.53
0.03 ± 3.53
0.03 ± 1.10
0.01 ± 1.03
0.04 ± 2.44
0.02 ± 1.21
0.01 ± 2.87
0.02 ± 0.23
0.03 ± 0.82
0.05 ± 2.87
0.03 ± 1.37
a. n = 3, average of three determinations.
... 5 Separation and determination of process-related impurities of Erlotinib using reverse phase HPLC with a photodiode array detector. 6 New derivative spectrophotometric methods for the determination of erlotinib hydrochloride (A tyrosine kinase inhibitor). 7 Development and validation of a stability indicating HPLC method for the quantification of impurities in erlotinib hydrochloride dosage forms. ...
Article
A simple, sensitive, precise, selective reverse phase high performance liquid chromatographic method was developed and validated for erlotinib hydrochloride in tablet dosage form.(0.02M)The separation was achieved on C18 column (150mm×4.6mm.i.d.,5.0μm) using potassium dihydrogen phosphate: acetonitrile in the ratio 50:50v/v as mobile phase having pH 4.5 was adjusted with methanol and flow rate 1ml/min. Detection was carried out using a UV detector at 248nm. The column temperature was adjusted at 30ᵒC. The method was validated for precision, linearity and range, stability and robustness. The developed and validated method was successfully applied for the quantitative analysis of ERLONAT tablets. The total chromatographic analysis time per sample was about 7min with Erlotinib eluting at 6.547min.Validation studies demonstrated that this HPLC method is simple, specific, rapid, reliable and reproducible. The standard curves were linear over the concentration ranges, 88.32- 132.48μg/ml for erlotinib. The high recovery confirms the suitability of the proposed method for the determination of Erlotinib in ERLONAT tablets. The results of analysis have been validated according to ICH guideline requirements. The method can be applied for Erlotinib hydrochloride tablets.
... The attempts were made to determine the process-related impurities and the development of stability-indicating assay method (SIAM) of ERLO. [11,12] No study so far has been reported on the systematic approach toward the characterization of degradation products (DPs) of ERLO under stress conditions prescribed by the International Conference on Harmonization (ICH) Q1A (R2). [36] Therefore, the present study was conducted considering a general interest to provide comprehensive information with respect to stability of ERLO and its degradation pathway. ...
Article
Full-text available
The present research work was carried out to determine the stability of erlotinib hydrochloride (ERLO) drug under different stress conditions recommended by International Conference on Harmonization (ICH) guideline Q1A (R2). The stability of the drug was studied under hydrolytic, oxidative, photolytic, and thermal stress conditions. The drug was found susceptible to degradation under acidic, basic, and photolytic stress conditions, while it was stable under neutral, oxidative, and thermal stress conditions. A total of three degradation products (DPs) were formed. Separation was carried out by using high-performance liquid chromatography system (HPLC). Better separation was achieved on Kromasil®(150 mm × 4.6 mm, 5 µm) C18 column using gradient elution program. A mixture of stressed samples was subjected to LC-MS/TOF studies to obtain mass spectral data. The information obtained from accurate mass study was first utilized to build a complete mass fragmentation pathway of the drug, and later it was used for its degradants. Structures were proposed for each fragment based on the best possible molecular formula. Three novel DPs 6-(2-hydroxyethoxy)-7-(2-methoxyethoxy)quinazolin-4-amine, 6,7-bis(2-methoxyethoxy)quinazolin-4-amine, and N-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-2-oxy-quinazolin-4-amine were identified.
... In continuation of the efforts to develop an HPLC method for the estimation of various intermediates=impurities formed during the synthesis of erlotinib HCl, [1] we have now taken up similar study for yet another method of synthesis of the drug via quinazoline-thione route. [2] Erlotinib hydrochloride, 6,7-bis(2-methoxyethoxy)-N-(3-ethynylphenyl) quinazolin-4-amine (Tarceva, R 1415, CP 358774, OSI 774, NSC 718781), is a drug used to treat non small cell lung cancer, pancreatic cancer, and several other types of cancer. ...
Article
Full-text available
A simple and rapid reverse-phase high-performance liquid chromatographic (RP-HPLC) method for the estimation of intermediates formed during the synthesis of anti-cancer drug erlotinib via quinazoline-thione route has been developed. The intermediates formed during the 7-step synthesis of erlotinib have been separated on a Inerstsil ODS-3 V (C18) column with isocratic elution using 1% ammonium acetate and acetonitrile (55:45 v/v) as mobile phase, with flow rate of 1 mL/min and detected at 254 nm using Photo Diode Array (PDA). The developed method was validated for accuracy, precision, linearity, limit of detection (LOD), limit of quantification (LOQ) and ruggedness. The correlation coefficients for calibration curves of intermediates were in the range of 0.995–0.999. The proposed reverse-phase HPLC method was successfully applied for the estimation of intermediates/impurities present in erlotinib bulk drug; the recoveries of intermediates were in the range of 96.83–100.96% and precision values were less than 3%. The method was found to be specific, precise, and reliable for the determination of intermediates and synthetic impurities in erlotinib bulk drug.
... Its monotherapy has demonstrated clinical activity in non-small cell cancer, head and neck cancer and ovarian cancer in Phase studies in USA 4-6 . Erlotinib HCl was determined by different analytical techniques such as liquid chromatography-mass spectrometry 7-11 and liquid chromatography 12-16 methods in biological samples, Spectrophotometry [17][18][19] , spectrofluorimetry 20-21 , UPLC 22 , HPTLC 23 and RP-HPLC [24][25][26][27][28][29][30] in pharmaceutical formulations. ...
Article
Full-text available
Three simple, rapid and sensitive spectrophotometric methods were developed for the determination of Erlotinib hydrochloride in pharmaceutical formulations. Beer’s law was obeyed over a concentration range 0.5-30 μg/mL in HCl and acetate buffer and 1-30 μg/mL in phosphate buffer. The linear regression equations were found to be y = 0.0717x + 0.0083, y = 0.0676x + 0.0102 and y = 0.0638x + 0.0096 in HCl, acetate buffer and phosphate buffer respectively and the three methods were validated as per ICH guidelines.
... Although several HPLC techniques have been developed for the assay of erlotinib, like liquid chromatographytandem mass spectrometry (LC/MS/MS) methods, there is still no simple and rapid HPLC method available for its quantification in clinical and pharmaceutical samples. [13][14][15][16][17][18] Therefore in the present study a simple, sensitive, rapid and effective HPLC method was developed and validated for quantification of erlotinib hydrochloride with the application to protein binding studies. ...
Article
Full-text available
Purpose: The aim of the present study was to develop a simple and rapid reversed-phase high performance liquid chromatographic method with UV detection for erlotinib hydrochloride quantification, which is applicable for protein binding studies. Methods: Ultrafilteration method was used for protein binding study of erlotinib hydrochloride. For sample analysis a simple and rapid reversed-phase high performance liquid chromatographic method with UV detection at 332 nm was developed. The mobile phase was a mixture of methanol, acetonitril and potassium dihydrogen phosphate buffer (15:45:40 %v/v) set at flow rate of 1.3 ml/min. Results: The run time for erlotinib hydrochloride was approximately 6 minutes. The calibration curve was linear over the range of 320-20000 ng/ml with acceptable intra- and inter-day precision and accuracy. The intra-day and inter-day precisions were less than 10% and the accuracies of intra and inter-day assays were within the range of 97.20-104.83% and 98.8-102.2% respectively. Conclusion: Based on the obtained results, a simple, accurate and precise reversed-phase isocratic HPLC method with UV detection has been optimized and validated for the determination of erlotinib hydrochloride in biological samples.
Article
Two different simple, accurate, and precise UV spectrophotometric methods have been developed for the estimation of erlotinib hydrochloride in bulk and tablet forms by the zero-order (method I) and the zero-order AUC (method II). The drug was dissolved in a phosphate buffer solution (pH 7.4), and at 228.20 nm the zero-order (method I) and at 224.20–230.20 nm the zero-order AUC (method II) were developed. For both methods, erlotinib has linearity in the concentration range 10–70 μg/mL, with a correlation coefficient R2 > 0.99. Both methods showed good reproducibility and recovery with %RSD less than 2 and an accuracy of 98.54–101.39 and 98.08–99.83%, respectively. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 1.16, 3.51, and 21.41, 64.90 μg/mL, respectively, for both methods.
Chapter
Erlotinib (OSI-774), marketed by Genentech as Tarceva®, is anticancer drug approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer. Erlotinib inhibited epidermal growth factor receptor (EGFR) that blocks tumor cell division, produces cell cycle arrest, and initiates programmed cell death in EGFR-overexpressing human tumor cells. This study presents a comprehensive profile of erlotinib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis). Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry. Chromatographic methods of analyses include thin layer chromatography, and high-performance liquid chromatography. Pharmacology of erlotinib including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented. An appropriate table and figures were attached to each of the above mentioned sections along with total of 48 references.
Article
Introduction: Erlotinib is a well known FDA approved drug from category of tyrosine kinase inhibitors; used for the treatment of lung cancer. However its use is limited because of its poor water solubility. Objective: The aim of present work was to improve solubility by developing a stable nanocrystal based drug delivery system of ERL with the aid of sodium lauryl sulfate as potential stabilizer and to carry out comparative evaluation of electrospraying and lyophilization as solidification techniques on its solid state properties. Experimental: Nanocrystal formulation was developed with antisolvent precipitation method having particle size, polydispersity index and zetapotential of 232.4±4.3nm, 0.162 and -9.82mV respectively. Further comparative evaluation of lyophilization and electrospraying was commenced as potential solidification techniques and solid powder matrix obtained from both the solidification techniques were compared in terms of size after re-dispersion (260±4.8 and 329±5.2nm respectively), particle morphology, surface area (0.984±0.11 and 0.341±0.05m(2)/g respectively), pore volume (0.0014 and 0.0009cm(3)/g respectively), solid state of drug present and % drug release (~100% and ~78% respectively in 600min). In vitro cytotoxicity studies shared that obtained formulation was having reduced IC50 values in comparison to drug. Further intracellular reactive oxygen species production was found to be higher for formulation treated cells when compared to free drug. Overall developed formulation was found to be potential drug delivery system for lung cancer therapy.
Article
Full-text available
The number of patients suffering from a cancer is constantly increasing and, consequently, the number of chemotherapies administered follows the same trend. Given the high reactivity and toxicity of the antineoplastic drugs, analytical methods are required in all the pharmaceutical fields: from drug development to their elimination in wastewater treatment plant, including formulation quality control, environment and human exposure as well as therapeutic drug monitoring. The aim of this paper is to provide an overview of the analytical methods available for the determination of antineoplastic drugs in different matrices such as pharmaceutical formulations, biological and environmental samples. The applicability and performance of the reported methods will be critically discussed, with a special focus on the most commonly used antineoplastic drugs. Only conventional compounds and small molecules of targered therapy will be considered in the present review.
Article
Full-text available
Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.
Article
Full-text available
A novel bioanalytical method was developed and validated for the quantitative determination of erlotinib in human plasma by using the supported liquid extraction (SLE) sample cleanup coupled with hydrophilic interaction liquid chromatography and tandem mass spectrometric detection (HILIC-MS/MS). The SLE extract could be directly injected into the HILIC-MS/MS system for analysis without the solvent evaporation and reconstitution steps. Therefore, the method is simple and rapid. In the present method, erlotinib-d 6 was used as the internal standard. The SLE extraction recovery was 101.3%. The validated linear curve range was 2 to 2,000 ng/mL based on a sample volume of 0.100-mL, with a linear correlation coefficient of > 0.999. The validation results demonstrated that the present method gave a satisfactory precision and accuracy: intra-day CV < 5.9% (<8.4% for the lower limit of quantitation, LLOQ) with n = 6 and the accuracy of 98.0– 106.0%; inter-day CV < 3.2% (<1.5% for LLOQ) with n = 18 and the accuracy of 100.0– 103.2%. A dilution factor of 10 with blank plasma was validated for partial volume analysis. The stability tests indicated that the erlotinib in human plasma is stable for three freeze-thaw cycles (100.0–104.5% of the nominal values), or 24-h ambient storage (100.0– 104.8% of the nominal values), or 227-day frozen storage at both -20 ºC (91.5–94.5% of the nominal values) and -70 ºC (93.3–93.8% of the nominal values). The results also OPEN ACCESS Pharmaceutics 2010, 2 106 showed no significant matrix effect (<6.3%) even with direct injection of organic extract into the LC-MS/MS system. The validated method has been successfully applied to support a clinical study.
Article
A simple stability-indicating high-performance liquid-chromatographic (HPLC) method for the assay of erlotinib in the presence of its degradation products was developed on a C18 column using a mobile phase of 0.01 M ammonium formate-acetonitrile-containing formic acid with a flow rate of 1.0 mL min-1. The method was validated. Selectivity was validated by subjecting the stock solution of erlotinib to acidic, basic, photolysis, oxidative, and thermal degradation. The linearity range and values for limits of detection (LOD) and quantification (LOQ) were found to be 1-198, 0.33, and 1.1 µg mL-1, respectively. The analysis of the tablets containing erlotinib was quite precise (relative standard deviation Keywords: Erlotinib; forced degradation; reverse phase; stability indicating; validation Document Type: Research Article DOI: http://dx.doi.org/10.1080/00032710903061170 Affiliations: 1: Department of Chemistry, Mangalore University, Mangalagangotri, India 2: Department of Chemistry, Karnatak University, Dharwad, India Publication date: August 1, 2009 $(document).ready(function() { var shortdescription = $(".originaldescription").text().replace(/\\&/g, '&').replace(/\\, '<').replace(/\\>/g, '>').replace(/\\t/g, ' ').replace(/\\n/g, ''); if (shortdescription.length > 350){ shortdescription = "" + shortdescription.substring(0,250) + "... more"; } $(".descriptionitem").prepend(shortdescription); $(".shortdescription a").click(function() { $(".shortdescription").hide(); $(".originaldescription").slideDown(); return false; }); }); Related content In this: publication By this: publisher By this author: Pujeri, S. S. ; Khader, A. M. A. ; Seetharamappa, J. GA_googleFillSlot("Horizontal_banner_bottom");
Article
A fast, sensitive, universal and accurate method for the determination of four different tyrosine kinase inhibitors from biological material was developed using LC-MS/MS techniques. Utilizing a simple protein precipitation with acetonitrile a 20 microl sample volume of biological matrixes can be extracted at 4 degrees C with minimal effort. After centrifugation the sample extract is introduced directly onto the LC-MS/MS system without further clean-up and assayed across a linear range of 1-4000 ng/ml. Chromatography was performed using a Dionex Ultimate 3000 with a Phenomenex prodigy ODS3 (2.0 mm x 100 mm, 3 microm) column and eluted at 200 microl/min with a tertiary mobile phase consisting of 20mM ammonium acetate:acetonitrile:methanol (2.5:6.7:8.3%). Injection volume varied from 0.1 microl to 1 microl depending on the concentration of the drug observed. Samples were observed to be stable for a maximum of 48 h after extraction when kept at 4 degrees C. Detection was performed using a turbo-spray ionization source and mass spectrometric positive multi-reaction-monitoring-mode (+MRM) for Gefitinib (447.1 m/z; 127.9 m/z), Erlotinib (393.9 m/z; 278.2 m/z), Sunitinib (399.1 m/z; 283.1 m/z) and Sorafenib (465.0 m/z; 251.9 m/z) at an ion voltage of +3500 V. The accuracy, precision and limit-of-quantification (LOQ) from cell culture medium were as follows: Gefitinib: 100.2+/-3.8%, 11.2 nM; Erlotinib: 101.6+/-3.7%, 12.7 nM; Sunitinib: 100.8+/-4.3%, 12.6 nM; Sorafenib: 93.9+/-3.0%, 10.8 nM, respectively. This was reproducible for plasma, whole blood, and serum. The method was observed to be linear between the LOQ and 4000 ng/ml for each analyte. Effectiveness of the method is illustrated with the analysis of samples from a cellular accumulation investigation and from determination of steady state concentrations in clinically treated patients.
Article
A high-performance liquid-chromatographic (HPLC) assay with UV detection has been developed for the quantitative determination of erlotinib (OSI-774) in human plasma. Quantitative extraction was achieved by a single-solvent extraction involving a mixture of acetonitrile and n-butyl chloride (1:4, v/v). Erlotinib and the internal standard hydrochloride salt (OSI-597) were separated on a column packed with Nova-Pak C18 material and a mobile phase composed of acetonitrile and water, pH 2.0 (60:40, v/v). The column effluent was monitored with dual UV detection at wavelengths of 348 nm (erlotinib) and 383 nm (OSI-597). The calibration graph was linear in the range of 100-4500 ng/ml, with values for accuracy and precision ranging from 87.9 to 96.2% and 2.13 to 5.10%, respectively, for three different sets of quality control samples. The developed method was successfully applied to study the pharmacokinetics of erlotinib in a cancer patient at the recommended daily dose of 150 mg.
Article
A new simple and specific method was developed and validated for the quantitative determination of OSI-774 (Tarceva, Erlotinib) and its metabolite, OSI-420, in human plasma. Sample pretreatment involved a single protein precipitation step with acetonitrile. The analytes were separated on Waters X-Terra C(18) (50 x 2.1 mm I.D., 3.5 microm) analytical column and eluted with acetonitrile-water mobile (70:30, v/v) containing 0.1% formic acid. The analytes of interest were monitored by tandem mass spectrometry with electrospray positive ionization. The overall extraction efficiency was greater than 88% for OSI-774 and 62% for OSI-420, with values for within-day and between-day precision and accuracy of <15%. Compared to previous assays, this method is simple, specific, and reproducible and will be used to characterize the plasma pharmacokinetics of OSI-774 at doses of 50 to 150 mg to optimize treatment with this agent.
Article
A qualitative and quantitative analysis of erlotinib (RO0508231) and its metabolites was carried out on rat tissue sections from liver, spleen and muscle. Following oral administration at a dose of 5 mg/kg, samples were analyzed by matrix-assisted laser desorption ionization (MALDI) with mass spectrometry (MS) using an orthogonal quadrupole time-of-flight instrument. The parent compound was detected in all tissues analyzed. The metabolites following drug O-dealkylation could also be detected in liver sections. Sinapinic acid (SA) matrix combined with the dried-droplet method resulted in better conditions for our analysis on tissues. Drug quantitation was investigated by the standard addition method and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis on the tissue extracts. The presence of the parent compound and of its O-demethylated metabolites was confirmed in all tissue types and their absolute amounts calculated. In liver the intact drug was found to be 3.76 ng/mg tissue, while in spleen and muscle 6- and 30-fold lower values, respectively, were estimated. These results were compared with drug quantitation obtained by whole-body autoradiography, which was found to be similar. The potential for direct quantitation on tissue sections in the presence of an internal standard was also investigated using MALDI-MS. The use of alpha-cyano-4-hydroxycinnamic acid (CHCA) as the matrix resulted in better linearity for the calibration curves obtained with reference solutions of the drug when compared to SA, but on tissue samples no reliable quantitative analysis was possible owing to the large variability in the signal response. MS imaging experiments using MALDI in MS/MS mode allowed visualizing the distribution of the parent compound in liver and spleen tissues. By calculating the ratio between the total ion intensities of MS images for liver and spleen sections, a value of 6 : 1 was found, which is in good agreement with the quantitative data obtained by LC-MS/MS analysis.
  • J Pan
  • X Jiang
  • Y L Chen
J. Pan, X. Jiang, and Y. L. Chen, Pharmaceutics, 2010, 2, 105.
  • L Signor
  • E Varesio
  • R F Staack
  • V Starke
  • W F Richter
  • G Hopfgartner
L. Signor, E. Varesio, R. F. Staack, V. Starke, W. F. Richter, and G. Hopfgartner, J. Mass Spectrom., 2007, 42, 900.